CA3021788C - Use of nalmefene in non-alcoholic steatohepatitis - Google Patents

Use of nalmefene in non-alcoholic steatohepatitis Download PDF

Info

Publication number
CA3021788C
CA3021788C CA3021788A CA3021788A CA3021788C CA 3021788 C CA3021788 C CA 3021788C CA 3021788 A CA3021788 A CA 3021788A CA 3021788 A CA3021788 A CA 3021788A CA 3021788 C CA3021788 C CA 3021788C
Authority
CA
Canada
Prior art keywords
compound
alcoholic
nash
alcoholic steatohepatitis
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3021788A
Other languages
English (en)
French (fr)
Other versions
CA3021788A1 (en
Inventor
Edwin Sc Wu
Peter J.S. Chiu
May Mei-Chi Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TaiwanJ Pharmaceuticals Co Ltd
Original Assignee
TaiwanJ Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TaiwanJ Pharmaceuticals Co Ltd filed Critical TaiwanJ Pharmaceuticals Co Ltd
Publication of CA3021788A1 publication Critical patent/CA3021788A1/en
Application granted granted Critical
Publication of CA3021788C publication Critical patent/CA3021788C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3021788A 2016-04-22 2017-04-20 Use of nalmefene in non-alcoholic steatohepatitis Active CA3021788C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662326435P 2016-04-22 2016-04-22
US62/326,435 2016-04-22
US201662395436P 2016-09-16 2016-09-16
US62/395,436 2016-09-16
PCT/US2017/028529 WO2017184819A1 (en) 2016-04-22 2017-04-20 Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
CA3021788A1 CA3021788A1 (en) 2017-10-26
CA3021788C true CA3021788C (en) 2021-08-03

Family

ID=58668969

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3021788A Active CA3021788C (en) 2016-04-22 2017-04-20 Use of nalmefene in non-alcoholic steatohepatitis

Country Status (10)

Country Link
US (1) US10045977B2 (enExample)
EP (1) EP3445363A1 (enExample)
JP (1) JP2019514872A (enExample)
KR (1) KR20180129909A (enExample)
CN (2) CN109069503A (enExample)
AU (1) AU2017253228B2 (enExample)
BR (1) BR112018071705A2 (enExample)
CA (1) CA3021788C (enExample)
RU (1) RU2717677C1 (enExample)
WO (1) WO2017184819A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
EP3712254A1 (en) 2014-05-28 2020-09-23 Children's Hospital Medical Center Methods and systems for converting precursor cells into gastric tissues through directed differentiation
CA2963704A1 (en) 2014-10-17 2016-04-21 Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
EP4177335A1 (en) 2016-05-05 2023-05-10 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
US20190247373A1 (en) * 2016-07-14 2019-08-15 Children's Hospital Medical Center Methods for treating fibrosis
SG11201903697WA (en) 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
EP3548507A4 (en) 2016-12-05 2020-07-15 Children's Hospital Medical Center COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF
EP3609997A4 (en) 2017-04-14 2021-03-03 Children's Hospital Medical Center COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES
US12297457B2 (en) 2017-10-10 2025-05-13 Children's Hospital Medical Center Esophageal tissue and/or organoid compositions and methods of making same
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
US12421500B2 (en) 2018-07-26 2025-09-23 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
JP2021535753A (ja) 2018-09-12 2021-12-23 チルドレンズ ホスピタル メディカル センター 造血幹細胞およびその派生体の生成のためのオルガノイド組成物
WO2020160371A1 (en) 2019-02-01 2020-08-06 The University Of Hong Kong Innervated organoid compositions and methods of making same
CA3141814A1 (en) 2019-05-31 2020-12-03 Children's Hospital Medical Center Shaped organoid compositions and methods of making same
CN114174494A (zh) 2019-05-31 2022-03-11 儿童医院医学中心 产生和扩增造血干细胞的方法
CA3236690A1 (en) 2021-11-18 2023-05-25 Ju Hee Kim Sustained-release injectable composition containing naltrexone and method for preparing same
CN118234488A (zh) 2021-11-18 2024-06-21 创技公司株式会社 包含难溶性药物的微粒的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
AU2003234621A1 (en) 2002-05-17 2003-12-02 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US7923454B2 (en) * 2002-05-17 2011-04-12 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
US10363251B2 (en) * 2009-07-16 2019-07-30 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
CN102048733B (zh) 2010-12-23 2011-12-28 武汉同源药业有限公司 盐酸纳美芬在制备治疗脂肪肝的药物中的用途
MY180160A (en) * 2013-04-22 2020-11-23 Cadila Healthcare Ltd A novel composition for nonalcoholic fatty liver disease (nafld)
EP3416619A2 (en) * 2016-02-18 2018-12-26 Immune Therapeutics, Inc. Method for inducing a sustained immune response

Also Published As

Publication number Publication date
BR112018071705A2 (pt) 2019-02-19
AU2017253228B2 (en) 2020-04-09
CN117137917A (zh) 2023-12-01
US20170304294A1 (en) 2017-10-26
RU2717677C1 (ru) 2020-03-25
CA3021788A1 (en) 2017-10-26
EP3445363A1 (en) 2019-02-27
AU2017253228A1 (en) 2018-09-27
AU2017253228A8 (en) 2019-01-17
KR20180129909A (ko) 2018-12-05
US10045977B2 (en) 2018-08-14
WO2017184819A1 (en) 2017-10-26
CN109069503A (zh) 2018-12-21
JP2019514872A (ja) 2019-06-06

Similar Documents

Publication Publication Date Title
AU2017253228B2 (en) Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease
JP2019514872A5 (enExample)
AU2020267217B2 (en) Therapeutic methods employing noribogaine and related compounds
CN110638805A (zh) 促进吸烟停止
CN106999467A (zh) 治疗认知减退的方法
CN107951869A (zh) 含有大麻二酚的药物制剂及其应用
Hu et al. Effect of Piper nigrum essential oil in dextran sulfate sodium (DSS)-induced colitis and its potential mechanisms
KR101558476B1 (ko) 필버톤의 신규한 용도
US20150306167A1 (en) Alpinia spp. extracts for treating irritable bowel syndrome
JP7759109B2 (ja) Ｅｏｍｅｓ陽性ＣＤ４陽性Ｔ細胞の増加に起因する進行型疾患治療剤
JP2015501849A5 (enExample)
US20160287578A1 (en) Toll-like receptor 4 antagonists and use in autoimmune liver diseases
US20180318290A1 (en) Use of nalmefene in non-alcoholic steatohepatitis
CN114555577A (zh) 用于治疗门静脉炎症和纤维化的噻吩衍生物
JP2019041675A (ja) Ｎａｓｈ肝発がんモデル非ヒト動物及びその使用
TW201813646A (zh) 納美芬(nalmefene)在非酒精性脂肪肝炎(nash)的應用
CN113368107B (zh) 包含小檗碱和苦参碱的药物组合物及其治疗或预防非酒精性脂肪性肝病的用途
CN106632378A (zh) 一种可抑制肥大细胞脱颗粒的化合物及其制备方法和用途
CN112972440A (zh) 麝香酮在制备防治抑郁症的药物中的用途
CN1647800A (zh) 一种河鲀油制剂及其制备方法
US20240058300A1 (en) Tocotrienol compositions and methods to treat non-alcoholic steatohepatitis
KR20190130241A (ko) 크로몰린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
CN105902527A (zh) 一种具有降低血糖作用的药物组合物及其制备方法和应用
KR101541016B1 (ko) 피노카베올의 신규한 용도
WO2022246586A1 (en) Use of a curcuminoid-rich oil extract for treating acute lung injury

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181019

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250327

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250327

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250327

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260416

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260416